The introduction of new treatments in haematological malignances, from targeted monoclonal antibodies to immune checkpoint inhibitors, has led to an increase in adverse effects (AEs)1,2 where gastrointestinal toxicities are some of the most commonly reported.
Brentuximab-related apoptotic colopathy / Parente, P; Graziano, P; Scalzulli, P; Mastracci, L; Grillo, F.. - In: PATHOLOGY. - ISSN 0031-3025. - April:25(2020). [10.1016/j.pathol.2020.02.011.]
Brentuximab-related apoptotic colopathy
Graziano P;
2020
Abstract
The introduction of new treatments in haematological malignances, from targeted monoclonal antibodies to immune checkpoint inhibitors, has led to an increase in adverse effects (AEs)1,2 where gastrointestinal toxicities are some of the most commonly reported.File allegati a questo prodotto
| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS0031302520307893.pdf
solo gestori archivio
Note: Parente_Brentuximab-related_2020
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
979.73 kB
Formato
Adobe PDF
|
979.73 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
